Predictors of early relapse in postmenopausal women with hormone receptor-positive breast cancer in the BIG 1-98 trial.

[1]  Robert C. G. Martin,et al.  Determinants of early distant metastatic disease in elderly patients with breast cancer. , 2006, American journal of surgery.

[2]  K. Jirström,et al.  High Progesterone Receptor Expression Correlates to the Effect of Adjuvant Tamoxifen in Premenopausal Breast Cancer Patients , 2006, Clinical Cancer Research.

[3]  G. Hortobagyi,et al.  Prognosis and management of patients with node-negative invasive breast carcinoma that is 1 cm or smaller in size (stage 1; T1a,bN0M0): a review of the literature. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  M. Dowsett,et al.  Benefit from adjuvant tamoxifen therapy in primary breast cancer patients according oestrogen receptor, progesterone receptor, EGF receptor and HER2 status. , 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

[5]  R W Blamey,et al.  Prognostic value of lymphovascular invasion in women with lymph node negative invasive breast carcinoma. , 2006, European journal of cancer.

[6]  J. Cuzick,et al.  Should aromatase inhibitors be used as initial adjuvant treatment or sequenced after tamoxifen ? , 2006 .

[7]  J. Forbes,et al.  A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. , 2005, The New England journal of medicine.

[8]  R. Schiff,et al.  Endocrine responsiveness: understanding how progesterone receptor can be used to select endocrine therapy. , 2005, Breast.

[9]  J. Cuzick,et al.  Retrospective analysis of time to recurrence in the ATAC trial according to hormone receptor status: an hypothesis-generating study. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  R. Gelber,et al.  Meeting highlights: international expert consensus on the primary therapy of early breast cancer 2005. , 2005, Annals of oncology : official journal of the European Society for Medical Oncology.

[11]  Adrian V. Lee,et al.  Estrogen receptor-positive, progesterone receptor-negative breast cancer: association with growth factor receptor expression and tamoxifen resistance. , 2005, Journal of the National Cancer Institute.

[12]  Michael Gnant,et al.  Switching of postmenopausal women with endocrine-responsive early breast cancer to anastrozole after 2 years' adjuvant tamoxifen: combined results of ABCSG trial 8 and ARNO 95 trial , 2005, The Lancet.

[13]  E. Winer,et al.  Optimizing adjuvant endocrine therapy in postmenopausal women with early-stage breast cancer: a decision analysis. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  Chiara Benedetto,et al.  Switching to anastrozole versus continued tamoxifen treatment of early breast cancer: preliminary results of the Italian Tamoxifen Anastrozole Trial. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  P. Neven,et al.  Association between HER-2/neu and the progesterone receptor in oestrogen-dependent breast cancer is age-related , 2005, Breast Cancer Research and Treatment.

[16]  P. Lønning,et al.  A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer* , 2004, The New England journal of medicine.

[17]  C. Osborne,et al.  Progesterone receptor status significantly improves outcome prediction over estrogen receptor status alone for adjuvant endocrine therapy in two large breast cancer databases. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  M. Baum.  The ATAC (Arimidex, Tamoxifen, Alone or in Combination) adjuvant breast cancer trial in postmenopausal patients: factors influencing the success of patient recruitment. , 2001, European journal of cancer.

[19]  J. Coindre,et al.  Obvious peritumoral emboli: an elusive prognostic factor reappraised. Multivariate analysis of 1320 node-negative breast cancers. , 1998, European journal of cancer.